Literature DB >> 10037388

Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants.

L S Cook1, M Goldoft, S M Schwartz, N S Weiss.   

Abstract

PURPOSE: We characterize the incidence of adenocarcinoma of the prostate among Chinese, Japanese and Filipino immigrants to the United States and their descendants.
MATERIALS AND METHODS: Subjects included 1,511 Asian and 16,000 white residents of Hawaii, San Francisco/Oakland and western Washington diagnosed with primary adenocarcinoma of the prostate during 1973 through 1986, and identified from the Surveillance, Epidemiology and End Results program. The size and composition of the population at risk were provided by a special tabulation of the 1980 United States Census.
RESULTS: Among Asian-Americans 45 to 69 years old the annual rate per 100,000 for Chinese (24.0), Japanese (29.6) and Filipino (56.8) men born in China, Japan and the Philippines, respectively, was approximately half that of United States born Chinese, Japanese and Filipino men (44.4, 42.2 and 111.3, respectively). For Japanese Americans 70 to 84 years old at diagnosis differences in incidence persisted between those born in Japan (238.0) and the United States (446.4), while for older Chinese Americans incidence rates were nearly the same for those born in China (428.3) and the United States (425.0). In contrast, older Filipino men born in the Philippines had a higher rate (400.1) than their United States born counterparts (264.9) but the latter rate was based on a small number of men. Among United States residents the annual incidence for all generations of Asian-Americans was roughly half that of white men born in the United States (215.9).
CONCLUSIONS: These results suggest that, irrespective of birthplace or age, Asian-American men retain 1 or more genetic or lifestyle characteristics that make their risk of prostate cancer less than that of white residents of the United States.

Entities:  

Mesh:

Year:  1999        PMID: 10037388

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  44 in total

1.  Studying cancer incidence and outcomes in immigrants: methodological concerns.

Authors:  Scarlett S Lin; Christina A Clarke; Cynthia D O'Malley; Gem M Le
Journal:  Am J Public Health       Date:  2002-11       Impact factor: 9.308

2.  Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men.

Authors:  Fang Liu; Ann W Hsing; Xiang Wang; Qiang Shao; Jun Qi; Yu Ye; Zhong Wang; Hongyan Chen; Xin Gao; Guozeng Wang; Lisa W Chu; Qiang Ding; Jun OuYang; Xu Gao; Yichen Huang; Yanbo Chen; Yu Tang Gao; Zuo-Feng Zhang; Jianyu Rao; Rong Shi; Qijun Wu; Meilin Wang; Zhengdong Zhang; Yuanyuan Zhang; Haowen Jiang; Jie Zheng; Yanlin Hu; Ling Guo; Xiaoling Lin; Sha Tao; Guangfu Jin; Jielin Sun; Daru Lu; S Lilly Zheng; Yinghao Sun; Zengnan Mo; Jianfeng Xu
Journal:  Cancer Sci       Date:  2011-08-10       Impact factor: 6.716

3.  Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients.

Authors:  V Balachandar; B Lakshman Kumar; K Sasikala; P Manikantan; R Sangeetha; S Mohana Devi
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

4.  Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin.

Authors:  Tze-Chen Hsieh; Joseph M Wu
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

5.  Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Authors:  Cindy Ke Zhou; David P Check; Joannie Lortet-Tieulent; Mathieu Laversanne; Ahmedin Jemal; Jacques Ferlay; Freddie Bray; Michael B Cook; Susan S Devesa
Journal:  Int J Cancer       Date:  2015-11-27       Impact factor: 7.396

Review 6.  Cancer and inflammation: promise for biologic therapy.

Authors:  Sandra Demaria; Eli Pikarsky; Michael Karin; Lisa M Coussens; Yen-Ching Chen; Emad M El-Omar; Giorgio Trinchieri; Steven M Dubinett; Jenny T Mao; Eva Szabo; Arthur Krieg; George J Weiner; Bernard A Fox; George Coukos; Ena Wang; Robert T Abraham; Michele Carbone; Michael T Lotze
Journal:  J Immunother       Date:  2010-05       Impact factor: 4.456

7.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

8.  Uncovering nativity disparities in cancer patterns: Multiple imputation strategy to handle missing nativity data in the Surveillance, Epidemiology, and End Results data file.

Authors:  Jane R Montealegre; Renke Zhou; E Susan Amirian; Michael E Scheurer
Journal:  Cancer       Date:  2014-01-16       Impact factor: 6.860

Review 9.  Inhibition of cancer cell invasion and metastasis by genistein.

Authors:  Janet M Pavese; Rebecca L Farmer; Raymond C Bergan
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

10.  Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.

Authors:  Elin Thysell; Izabella Surowiec; Emma Hörnberg; Sead Crnalic; Anders Widmark; Annika I Johansson; Pär Stattin; Anders Bergh; Thomas Moritz; Henrik Antti; Pernilla Wikström
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.